Bioatla announces second quarter 2021 financial results and provides clinical update

San diego, aug. 13, 2021 /prnewswire/ -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics, today announced financial results for the second quarter of 2021 and provided an update on its business. "bioatla is advancing potentially registration-enabling phase 2 clinical trials for our two lead cab product candidates.
BCAB Ratings Summary
BCAB Quant Ranking